{
    "ticker": "OBT",
    "name": "Obsidian Therapeutics, Inc.",
    "description": "Obsidian Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with unmet medical needs. Founded in 2015, Obsidian is pioneering the field of gene therapy and cellular engineering, utilizing its proprietary technology platforms to create advanced cell therapies. The company\u2019s unique approach allows for precise control over the expression of therapeutic genes, enabling more effective and safer treatments. Obsidian is particularly focused on applications in cancer immunotherapy, autoimmune diseases, and genetic disorders. The company's lead programs involve engineered T cells that are designed to enhance the immune response against tumors while minimizing side effects. Obsidian\u2019s mission is to harness the power of the body\u2019s immune system to fight disease and improve patient outcomes. The company is committed to advancing science through rigorous research and collaboration with leading academic institutions and industry partners. With a strong pipeline of product candidates, Obsidian is positioned to make significant contributions to the field of personalized medicine.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.obsidiantx.com",
    "ceo": "Paul W. Scherer",
    "social_media": {
        "twitter": "https://twitter.com/ObsidianTx",
        "linkedin": "https://www.linkedin.com/company/obsidian-therapeutics"
    },
    "investor_relations": "https://investors.obsidiantx.com",
    "key_executives": [
        {
            "name": "Paul W. Scherer",
            "position": "CEO"
        },
        {
            "name": "Andrew H. Schreiber",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapies",
            "products": [
                "Engineered T Cells"
            ]
        },
        {
            "category": "Gene Therapy",
            "products": [
                "Therapeutic Gene Constructs"
            ]
        }
    ],
    "seo": {
        "meta_title": "Obsidian Therapeutics, Inc. | Innovative Gene and Cell Therapy Solutions",
        "meta_description": "Learn about Obsidian Therapeutics, Inc., a leader in biotechnology focused on gene and cell therapy innovations for cancer and genetic disorders.",
        "keywords": [
            "Obsidian Therapeutics",
            "Biotechnology",
            "Gene Therapy",
            "Cell Therapy",
            "Cancer Immunotherapy"
        ]
    },
    "faq": [
        {
            "question": "What does Obsidian Therapeutics focus on?",
            "answer": "Obsidian Therapeutics focuses on developing innovative gene and cell therapies for unmet medical needs."
        },
        {
            "question": "Who is the CEO of Obsidian Therapeutics?",
            "answer": "Paul W. Scherer is the CEO of Obsidian Therapeutics, Inc."
        },
        {
            "question": "Where is Obsidian Therapeutics headquartered?",
            "answer": "Obsidian Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Obsidian's main products?",
            "answer": "Obsidian's main products include engineered T cells and therapeutic gene constructs."
        },
        {
            "question": "When was Obsidian Therapeutics founded?",
            "answer": "Obsidian Therapeutics was founded in 2015."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "SGMO"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "MRNA",
        "BMY"
    ]
}